Are There Therapeutic Implications of Targeting Mitochondrial Ribosomes in Cancer?
Targeting mitochondrial ribosomes offers a novel approach for cancer therapy. By specifically inhibiting mitochondrial protein synthesis, it may be possible to selectively target cancer cells without affecting normal cells. Antibiotics like tetracyclines, which inhibit mitochondrial translation, have shown promise in preclinical studies as potential anticancer agents. However, the challenge lies in developing selective inhibitors that can target mitoribosomes without causing excessive toxicity to normal cells.
